- CVD accounts for
1 in 3 deaths
- Someone has a heart
every 40 seconds
- CVD expenses, including stroke, were $351.2 billion in 2014-2015, including the cost of
healthcare services, medications, and lost productivity
Survey), estimates that 62.6 million US adults have elevated levels of LDL-C (also known as
hypercholesterolemia) and are eligible to use statins.3*
In the US, increasing attention has been placed on aggressive LDL-C reduction. This has led to the use of a combination of a statin with additional non-statin therapies.4
LDL-C=low-density lipoprotein cholesterol.
However, not all patients can tolerate statins or reach their LDL-C target on maximally-tolerated
- Approximately 27.4 million US adults with elevated LDL-C levels are taking a statin3
- Approximately 19.4 million patients with elevated LDL-C levels are currently unable to achieve their LDL-C target despite taking statin therapy3
hypercholesterolemia (HeFH) who require additional LDL-C lowering on top of maximally-tolerated
statin therapy represent a high-risk patient population with an unmet medical need.3,8
*Statin eligibility is one of the following (not mutually exclusive): ASCVD; LDL-C≥190 mg/dL; 40-75 y.o. with diabetes, LDL-C 70-189 mg/dL, without ASCVD; 40-75 y.o. without ASCVD or diabetes, with LDL-C 70-189 mg/dL and ≥7.5%
10-year ASCVD risk.
statistics—2019 update: a report from the American Heart Association.
https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed February 15,
3. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of
Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein
cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012.
Clinical Practice Guidelines.
7. Raymond C, Cho L, Rocco M, Hazen SL. New guidelines for reduction of blood cholesterol: Was it worth the wait?
al. for the European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary